Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

• by Máté Orgoványi, Anett Rancz, Anca Dolhascu, Gergely Agócs, Boglárka Lilla Szentes, Emese Sipter, Péter Hegyi, Gábor László Kovács

• July 2, 2026

Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study

• by Qiuqiu Zhang, Kailiang Xu, Zhongjun Chen, Zihui Li, Dong Zhao

• July 1, 2026

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

• July 1, 2026

• 1 min

Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment: a multicenter study integrating urodynamics and patient-reported outcomes

• by Krzysztof Bereza, Andrzej Kukiełka, Dominika Trojnarska, Beniamin Oskar Grabarek, Marcin Opławski, Tomasz Banaś

• July 2, 2026